Cargando…
412. Clinical and Pharmacoeconomic Evaluation of Antifungal Prophylaxis With Continuous Micafungin Compared to Posaconazole With Micafungin Bridging in Patients Undergoing Allogeneic Stem Cell Transplantation: A 6-Year Cohort Analysis
BACKGROUND: Patients undergoing allogeneic stem-cell transplantation (aSCT) are at high risk of invasive fungal disease (IFD). Optimization of antifungal prophylaxis strategies may further improve patient outcomes and reduce treatment costs. METHODS: We performed a retrospective single-center pharma...
Autores principales: | Heimann, Sebastian M, Vehreschild, Maria J G T, Franke, Bernd, Cornely, Oliver, Hamprecht, Axel, Piepenbrock, Ellen, Scheid, Christoph, Vehreschild, Janne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254699/ http://dx.doi.org/10.1093/ofid/ofy210.423 |
Ejemplares similares
-
Micafungin as antifungal prophylaxis in non-transplanted haemotological patients
por: Villaescusa, Teresa, et al.
Publicado: (2020) -
Pooled analysis of safety for micafungin
por: Cornely, OA, et al.
Publicado: (2008) -
Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants
por: Grau, Santiago, et al.
Publicado: (2015) -
Micafungin induced apoptosis in Candida parapsilosis independent of its susceptibility to micafungin
por: Shirazi, Fazal, et al.
Publicado: (2015) -
Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC)
por: López-Sánchez, Cristina, et al.
Publicado: (2020)